Steroids After Laser Trabeculoplasty for Glaucoma (SALT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00981435|
Recruitment Status : Completed
First Posted : September 22, 2009
Results First Posted : April 14, 2017
Last Update Posted : April 14, 2017
|Condition or disease||Intervention/treatment||Phase|
|Glaucoma||Drug: Prednisolone 1% Drug: Diclofenac 0.1% Drug: Artificial Tears||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||97 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Steroids And Laser Trabeculoplasty (SALT) Trial: Effect of Anti-Inflammatory Treatment on the Efficacy of SLT|
|Study Start Date :||September 2009|
|Actual Primary Completion Date :||September 2015|
|Actual Study Completion Date :||September 2015|
Experimental: Artificial Tears
Topical artificial tears dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
Drug: Artificial Tears
Artificial saline tears to lasered eye 4 times/day for 4.5 days
Other Name: saline tears
Experimental: Non-steroidal anti-inflammatory
Topical diclofenac 0.1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
Drug: Diclofenac 0.1%
Diclofenac sodium 0.1% to lasered eye 4 times/day for 4.5 days
Other Name: Voltaren
Topical prednisolone 1% dosed 4 times per day for 4 days in treated eye after laser trabeculoplasty.
Drug: Prednisolone 1%
Prednisolone 1% to lasered eye 4 times/day for 4.5 days
Other Name: Pred forte
- Intraocular Pressure (IOP) Change [ Time Frame: Baseline to Week 12 ]IOP will be measured before and at 6 and 12 weeks after intervention using Goldman tonometry.
- Intraocular Inflammation [ Time Frame: Up to week 12 ]The count of patients with inflammation defined as anterior chamber cells was measured in each study arm.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00981435
|United States, Florida|
|Bascom Palmer Eye Institute|
|Miami, Florida, United States, 33136|
|United States, Pennsylvania|
|University of Pittsburgh Medical Center|
|Pittsburgh, Pennsylvania, United States, 15213|
|Principal Investigator:||Jeffrey L Goldberg, MD, PhD||Stanford University|